Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-09
2011-08-09
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S085400, C424S085600, C424S085700, C424S143100, C424S144100, C424S173100
Reexamination Certificate
active
07993648
ABSTRACT:
A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
REFERENCES:
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), De Boer et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5801227 (1998-09-01), Fanslow et al.
patent: 5849898 (1998-12-01), Seed et al.
patent: 5874082 (1999-02-01), De Boer
patent: 6004552 (1999-12-01), De Boer
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6056959 (2000-05-01), De Boer et al.
patent: 6132978 (2000-10-01), Gelfand
patent: 6132992 (2000-10-01), Ledbetter
patent: 6312693 (2001-11-01), Aruffo et al.
patent: 6315998 (2001-11-01), De Boer et al.
patent: 6410711 (2002-06-01), Armitage et al.
patent: 6413514 (2002-07-01), Aruffo et al.
patent: 6497876 (2002-12-01), Maraskovsky et al.
patent: 6653104 (2003-11-01), Goldenberg
patent: 6838261 (2005-01-01), Siegall
patent: 6843989 (2005-01-01), Siegall et al.
patent: 6946129 (2005-09-01), Siegall et al.
patent: 7063845 (2006-06-01), Mikayama et al.
patent: 7172759 (2007-02-01), Thomas et al.
patent: 7193064 (2007-03-01), Mikayama et al.
patent: 7288251 (2007-10-01), Bedian et al.
patent: 7288252 (2007-10-01), Chu et al.
patent: 7338660 (2008-03-01), Bedian et al.
patent: 7361345 (2008-04-01), De Boer et al.
patent: 7368106 (2008-05-01), Murphy et al.
patent: 7387271 (2008-06-01), Noelle et al.
patent: 7404950 (2008-07-01), Spencer
patent: 7405270 (2008-07-01), Armitage et al.
patent: 7498032 (2009-03-01), Siegall
patent: 7510711 (2009-03-01), Siegall
patent: 7537763 (2009-05-01), Mikayama et al.
patent: 7547438 (2009-06-01), Thomas et al.
patent: 7563442 (2009-07-01), Bedian et al.
patent: 7618633 (2009-11-01), Bedian et al.
patent: 7626012 (2009-12-01), Bedian et al.
patent: 7666422 (2010-02-01), Siegall et al.
patent: 7790166 (2010-09-01), De Boer et al.
patent: 7820170 (2010-10-01), Chu et al.
patent: 7820807 (2010-10-01), Thomas et al.
patent: 7824683 (2010-11-01), Siegall et al.
patent: 2001/0026932 (2001-10-01), Thomas et al.
patent: 2002/0086026 (2002-07-01), Heath
patent: 2002/0106371 (2002-08-01), De Boer
patent: 2002/0142358 (2002-10-01), Mikayama et al.
patent: 2003/0022860 (2003-01-01), Melief et al.
patent: 2003/0059427 (2003-03-01), Force et al.
patent: 2003/0068299 (2003-04-01), Murphy et al.
patent: 2003/0099644 (2003-05-01), Ahuja et al.
patent: 2003/0118588 (2003-06-01), Diehl et al.
patent: 2003/0211100 (2003-11-01), Bedian et al.
patent: 2004/0109857 (2004-06-01), Chu et al.
patent: 2004/0120948 (2004-06-01), Mikayama et al.
patent: 2004/0141950 (2004-07-01), Noelle et al.
patent: 2004/0197312 (2004-10-01), Moskalenko et al.
patent: 2004/0235074 (2004-11-01), Siegall
patent: 2005/0002916 (2005-01-01), Jooss et al.
patent: 2005/0043517 (2005-02-01), Giles-Komar et al.
patent: 2005/0136055 (2005-06-01), Gladue et al.
patent: 2005/0180983 (2005-08-01), Keler et al.
patent: 2005/0255106 (2005-11-01), Diehl et al.
patent: 2005/0266002 (2005-12-01), Siegall
patent: 2006/0062784 (2006-03-01), Grant et al.
patent: 2009/0081157 (2009-03-01), Kornbluth et al.
Skolnick et al., Trends in Biotech. 18(1): 34 39, 2000.
Belardelli et al., Cytokine & Growth Factor Reviews 12: 119-134, 2002.
Attwood, Science 2000; 290:471-473, 2000.
Boon, Int. J. Cancer 54: 177-1980, 1993.
Spitler, Cancer Biotherapy 10: 1-3, 1995.
Ezzell, J. NIH Research 7: 46-49, 1995.
International Search Report, PCT Application No. PCT/US07/10690, dated Nov. 13, 2007, 9 pages.
Taraban et al., Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs1, The Journal of Immunology Cutting Edge, 2004, pp. 6542-6546.
Di Pucchio et al., “Immunization of Stage IV Melanoma Patients with Melan-A-Mart-1 and gp100 Peptides IFN-α Results in the Activation of Specific CD8+T Cells and Monocyte/Dendritic Cell Precursors”, Research Article, www.aacrjournals.org, Cancer Res 2006; 66: (9). May 1, 2006; pp. 4943-4951.
Ahonen et al., “Combined T1R and CD40 Triggering Induces Potent CD8+T Cell Expansion with Variable Dependence on Type I IFN”, The Journal of Experimental Medicine, vol. 199, No. 6, Mar. 15, 2004, pp. 775-784.
Luft et al., IFN-Alpha Enhances CD40 Ligand-Mediated Activation of Immature Monocyte-Derived Dendritic Cells; International Immunology, vol. 14, No. 4 (2002) pp. 367-380.
Kornbluth et al., Immunostimulatory Combinations: Designing the Next Generation of Vaccine Adjuvants; Journal of Leukocyte Biology, vol. 80, No. 5 (Nov. 2006) pp. 1084-1102.
European Search Report dated Jun. 15, 2010 (EP App. No. 07776857.4).
Santini et al., The Natural Alliance Between Type 1 and Interferon and Dendritic Cells and Its Role in Linking Innate and Adaptive Immunity, Journal of Interferon & Cytokine Research, vol. 22, No. 11, Nov. 2002, pp. 1071-1080.
Haluszczak Catherine
Kedl Ross
Sanchez Phillip J.
Gambel Phillip
Hunton & Williams LLP
The Regents of the Universitry of Colorado
LandOfFree
Immunostimulatory regimen comprising administering type 1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory regimen comprising administering type 1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory regimen comprising administering type 1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697440